BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28469731)

  • 21. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
    Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
    Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.
    Xue G; Lin X; Wu JF; Pei D; Wang DM; Zhang J; Zhang WJ
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32766727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
    Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors.
    Bisarro Dos Reis M; Barros-Filho MC; Marchi FA; Beltrami CM; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4089-4099. PubMed ID: 28938489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
    Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray analysis of papillary thyroid cancers in Korean.
    Kim HS; Kim DH; Kim JY; Jeoung NH; Lee IK; Bong JG; Jung ED
    Korean J Intern Med; 2010 Dec; 25(4):399-407. PubMed ID: 21179278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.
    Ortiz IMDP; Barros-Filho MC; Dos Reis MB; Beltrami CM; Marchi FA; Kuasne H; do Canto LM; de Mello JBH; Abildgaard C; Pinto CAL; Kowalski LP; Rogatto SR
    Clin Epigenetics; 2018 Nov; 10(1):144. PubMed ID: 30454026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
    Mishra NK; Guda C
    Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
    Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
    Wang J; Duan Y; Meng QH; Gong R; Guo C; Zhao Y; Zhang Y
    PLoS One; 2018; 13(10):e0203155. PubMed ID: 30286088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
    Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
    Oler G; Camacho CP; Hojaij FC; Michaluart P; Riggins GJ; Cerutti JM
    Clin Cancer Res; 2008 Aug; 14(15):4735-42. PubMed ID: 18676742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
    Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
    Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
    Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
    Huang Y; de la Chapelle A; Pellegata NS
    Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic Alterations and Canonical Pathway Disruption in Papillary Thyroid Cancer: A Genome-wide Methylation Analysis.
    White MG; Nagar S; Aschebrook-Kilfoy B; Jasmine F; Kibriya MG; Ahsan H; Angelos P; Kaplan EL; Grogan RH
    Ann Surg Oncol; 2016 Jul; 23(7):2302-9. PubMed ID: 26979305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.